Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Lilly stock dips after fake Twitter profile makes bogus insulin announcement

By Brian Buntz | November 14, 2022

Eli LillyEli Lilly‘s (NYSE:LLY) share price dropped about 4% Friday to $352.36 after a fake Twitter account claimed the company would make insulin available at no cost.

“We are excited to announce insulin is free now,” read the fake announcement from @EliLillyandCo, which received more than 1,500 retweets and 10,000 likes before Twitter removed the bogus announcement.

“We apologize to those who have been served a misleading message from a fake Lilly account. Our official Twitter account is @LillyPad,” the company announced on Twitter.

Today, LLY shares ticked up about 1% in mid-day trading to $355.53.

November 14 was World Diabetes Day.

Public Citizen and more than 50 other organizations wrote a letter to congressional leaders urging legislation that guarantees more-affordable insulin pricing.

Twitter withdrew its paid subscription service that some users used to exploit the service by impersonating companies and celebrities.

The news has highlighted the cost of Lilly’s insulins. For instance, a vial of its Humalog insulin costs $274.70 without insurance.

Lilly has responded to the renewed attention on its pricing by describing its affordability programs. For example, as part of the Lilly Insulin Value Program, the company’s insulins cost consumers $35 monthly for eligible patients regardless of whether they have insurance.

On Twitter, Lilly highlighted a Tweet stating that the company has “a comprehensive suite of insulin affordability solutions available.”

In 2016, Lilly announced that it would offer substantial insulin discounts to uninsured U.S. patients for its Humalog, Humulin and Basaglar insulins.

Lilly was not the only company to encounter problems with impersonation. For instance, an account claiming to represent Lockheed Martin Corp claimed the company would halt weapons sales to several countries. A bogus Nintendo account also made an appearance. In addition, Fake accounts also appeared, posing as professional basketball player LeBron James and former President George W. Bush.

Since taking over Twitter, Elon Musk has fired many employees while announcing new product ideas.

Lilly recently announced third-quarter 2022 financial results, seeing its revenue increase 2%, or 7% on a constant currency basis, year over year.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE